Diabetes Drugs Are Good for the Heart

Moderator(s)

• 

  Hemalkumar Mehta, MS, PhD (he/him/his)

  Associate Professor
  Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health
  Baltimore, United States
• AS

  Alexandra Sosinsky, ScM (she/her/hers)

  Director, Pharmacoepidemiology & Safety
  Genesis Research Group
  Holliston, United States

Presentations:

• 8:30 AM – 8:45 AM CEST

  Evaluating concordance in results from database studies and randomized trials after aligning distribution of key risk factors for the outcome of interest
  

  Presenting Author: Phyo T. Htoo, MD, PhD – Brigham and Women's Hospital and Harvard Medical School

  Co-Author: Elisabetta Patorno, MD, DrPH (she/her/hers) – Brigham and Women's Hospital and

  Co-Author: Sebastian Schneeweiss, MD, ScD (he/him/his) – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School

  Co-Author: Shirley V. Wang, PhD (she/her/hers) – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
• 8:45 AM – 9:00 AM CEST

  A Novel High Dimensional Approach to Assess Treatment Heterogeneity in Claims Data: Sodium-glucose Cotransporter-2 inhibitors (SGLT2i) vs Glucagon-like Peptide-1 Receptor Agonists (GLP1RA) on Hospitalized Heart Failure Risk
  

  Presenting Author: Tiansheng Wang, PharmD, PhD – University of North Carolina at Chapel Hill

  Co-Author: Virginia Pate, MS – University of North Carolina at Chapel Hill

  Co-Author: Richard Wyss, PhD – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

  Co-Author: John Buse, MD, PhD – University of North Carolina School of Medicine Division of Endocrinology and Metabolism

  Co-Author: Michael Kosorok – University of North Carolina Gillings School of Global Public Health Department of Biostatistics

  Co-Author: Til Stürmer, MD, PhD (he/him/his) – University of North Carolina at Chapel Hill
• 9:00 AM – 9:15 AM CEST

  The risk of cardiovascular (CV) events after initiation of SGLT2i, GLP-1RA, DPP4i, or SUs in patients with T2D and low-to-moderate CV risk
  

  Presenting Author: Helen Tesfaye, PharmD, MSc – Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School

  Co-Author: Julie M. Paik, MD, ScD – Brigham and Women's Hospital

  Co-Author: Caroline Alix, BA – Brigham and Women's Hospital

  Co-Author: Elyse C. DiCesare, BA – Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School

  Co-Author: Sara J. Cromer, MD – Massachusetts General Hospital

  Co-Author: Brendan M. Everett, MD, MPH – Brigham and Women’s Hospital

  Co-Author: Robert J. Glynn, PhD, ScD – Brigham and Women's Hospital

  Co-Author: Deborah J. Wexler, MD, MSc – Massachusetts General Hospital

  Co-Author: Elisabetta Patorno, MD, DrPH (she/her/hers) – Brigham and Women's Hospital and
• 9:15 AM – 9:30 AM CEST

  Initiation of SGLT2i vs GLP1-RA and the Risk of Chronic Kidney Disease in Persons with Type 2 Diabetes Mellitus
  

  Presenting Author: Simon K. Jensen, MD, PhD (he/him/his) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

  Co-Author: Uffe Heide-Jørgensen, MSc, PhD – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital

  Co-Author: Ina T. Andersen, PhD – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital

  Co-Author: Reimar W W. Thomsen, MD, PhD – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital

  Co-Author: Christian Fynbo Christiansen, MD, PhD – Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital
• 9:30 AM – 9:45 AM CEST

  Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study
  

  Co-Author: Arvid Engström, MD – Clinical Epidemiology Division

  Co-Author: Jonas Söderling – Clinical Epidemiology Division, Karolinska Institutet

  Co-Author: Anders Hviid – Statens Serum Institut

  Co-Author: Björn Eliasson – Sahlgrenska University Hospital

  Co-Author: Soffia Gudbjörnsdottir – University of Gothenburg

  Co-Author: Viktor Wintzell, PhD – Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

  Co-Author: Kristian Hveem – Norwegian University of Science and Technology

  Co-Author: Christian Jonasson – Norwegian University of Science and Technology

  Co-Author: Mads Melbye – Danish Cancer Institute

  Presenting Author: Björn Pasternak, MD, PhD – Clinical Epidemiology Division, Karolinska Institutet

  Co-Author: Peter Ueda – Karolinska Institutet
• 9:45 AM – 10:00 AM CEST

  Head-to-head Comparison of Dapagliflozin vs Empagliflozin: Cardiovascular and Safety Events
  

  Presenting Author: Elisabetta Patorno, MD, DrPH (she/her/hers) – Brigham and Women's Hospital and

  Co-Author: HoJin Shin, BPharm, PhD – Brigham and Women's Hospital

  Co-Author: Julie M. Paik, MD, ScD – Brigham and Women's Hospital

  Co-Author: Brendan M. Everett, MD, MPH – Brigham and Women’s Hospital

  Co-Author: Robert J. Glynn, PhD, ScD – Brigham and Women's Hospital

  Co-Author: Deborah J. Wexler, MD, MSc – Massachusetts General Hospital